<DOC>
	<DOCNO>NCT00063401</DOCNO>
	<brief_summary>The purpose study determine progression-free survival obtain cetuximab ( C225 ) /paclitaxel/carboplatin subject newly diagnose advanced stage ovarian , primary peritoneal , fallopian tube cancer .</brief_summary>
	<brief_title>Phase II Study Patients With Epidermal Growth Factor Receptor ( EGFR ) + Advanced Stage Ovarian , Primary Peritoneal Fallopian Tube Cancer</brief_title>
	<detailed_description>The population study trial subject advance stage ovarian , primary peritoneal fallopian tube cancer enrol . By receive combination therapy cetuximab ( C225 ) /paclitaxel/carboplatin , subject experience longer progression-free survival previously report subject receive paclitaxel carboplatin .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Inclusion Criteria 1 . Subjects must sign approve informed consent . 2 . Subjects histologic diagnosis epithelial ovarian carcinoma , primary peritoneal carcinoma , fallopian tube carcinoma , Stage III IV , either optimal ( ≤ 1 cm residual disease ) suboptimal residual disease follow initial surgery . All subject must appropriate surgery ovarian , primary peritoneal , fallopian tube carcinoma appropriate tissue available histologic evaluation . Pathology must verify participate institution 3 . Subjects follow histologic epithelial cell type eligible : Serous adenocarcinoma , endometrioid adenocarcinoma , mucinous adenocarcinoma , undifferentiated carcinoma , clear cell adenocarcinoma , mixed epithelial carcinoma , transitional cell carcinoma , malignant Brenner 's Tumor , adenocarcinoma N.O.S . 4 . Subjects tumor tissue available assessment EGFR status IHC . 5 . EGFR expression must positive ( e.g. , 1+ ) . 6 . Subjects must Karnofsky Performance Status ( KPS ) ≥ 70 % . 7 . Subjects must enter 12 week postoperatively . 8 . Women , age 18 older . 9 . Bone marrow function : absolute neutrophil count ( ANC ) ≥ 1,500/ul , equivalent Common Toxicity Criteria ( CTC ) grade 1 . Platelets ≥ institutional low limit normal ( LLN ) , CTC grade 0 . 10 . Renal function : creatinine ≤ 1.5 x institutional upper limit normal ( ULN ) , CTC grade 1 . 11 . Hepatic function : bilirubin ≤ 1.5 x ULN , CTC grade 1 . AST ≤ 2.5 x ULN , CTC grade 1 . 12 . Neurologic function : neuropathy ( sensory ) ≤ CTC grade 1 . Exclusion Criteria 1 . WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 4 week study . 2 . WOCBP use prohibit contraceptive method . 3 . Women pregnant breastfeed 4 . Women positive pregnancy test enrollment prior study drug administration . 5 . Subjects current diagnosis epithelial ovarian tumor low malignant potential ( borderline carcinoma ) eligible . Subjects prior diagnosis low malignant potential tumor surgically resect subsequently develop invasive adenocarcinoma eligible , provide receive prior chemotherapy ovarian tumor . 6 . Subjects receive prior radiotherapy portion abdominal cavity pelvis exclude . Prior radiation localize cancer breast , head neck , skin permit , provide complete 3 year prior registration , subject remain free recurrent metastatic disease . 7 . Subjects receive prior chemotherapy abdominal pelvic tumor exclude . Subjects may receive prior adjuvant chemotherapy localize breast cancer , provide complete 3 year prior registration , subject remain free recurrent metastatic disease . 8 . With exception nonmelanoma skin cancer specific malignancy note , subject invasive malignancy ( ) evidence cancer present within last 5 year whose previous cancer treatment contraindicate protocol therapy exclude . 9 . Subjects acute hepatitis . 10 . Subjects active uncontrolled infection eligible . 11 . Subjects significant history cardiac disease , i.e. , uncontrolled hypertension , unstable angina , congestive heart failure . 12 . Subjects leave ventricular ejection fraction ( LVEF ) institutional range normal baseline multiple gated acquisition ( MUGA ) scan echocardiogram . 13 . A history prior cetuximab therapy target EGFR pathway history prior chimerized murine monoclonal antibody therapy . 14 . Subjects know allergy murine protein Cremophor EL .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>ovarian</keyword>
	<keyword>primary peritoneal cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
</DOC>